[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tampere University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":701},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,41,67,93,120,142,168,200,232,262,287,325,348,377,404,435,464,494,520,551,582,603,629,653,676],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100652971","three-dimensional-molds-based-on-radiological-images-in-patients-with-cancer-the-direct-trial-100652971",false,"NCT07778173","Three-Dimensional Molds Based on Radiological imagEs in Patients With Cancer: the DIRECT Trial","DIRECT","Inclusion Criteria:\n\nTo be eligible for the study, the study candidate must:\n\n* be willing and able to give informed consent and give their written consent for the participation in the study (in case of a child (\\\u003C15-year-old), the consent is collected in an age-appropriate manner from the study candidate and their legal guardian(s))\n* have a malignant or likely malignant tumor\u002Ftumors and undergo a surgical operation.\n\nExclusion Criteria:\n\nTo be eligible for the study, the study candidate cannot:\n\n* lack the capacity to provide informed consent (if a legal guardian objects to the participation of their child (\\\u003C15-year-old), the child is not eligible);\n* be at risk of having their standard of care treatment jeopardized by the study, in the opinion of their physician.","ALL",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","Determination of the sites from which the histopathological samples in surgically removed lesions are collected is still done by eye by a pathologist. As radiological determination of regions of interest has already proven useful in in vivo use cases, the implementation of sampling of ex vivo lesions with the help of radiological imaging suggests great potential. By developing and implementing mold printing processes, these molds have the potential to vastly improve the accuracy and consistency of histopathological sampling and collection of tissue samples from different regions of tumor, leading to improved characterization, more individualized treatments, and eventually better survival.",[26,27],"Cancer","Tumor","RECRUITING","2026-08-20",{"date":31,"type":32},"2026-08-21","ACTUAL",{"date":34,"type":32},"2024-05-31",{"date":36,"type":20},"2033-12-15",{"name":38,"class":39},"Tampere University Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":40},"100552170","study-on-female-patients-mammographic-texture-features-100552170","NCT06469606","Study on Female Patients' Mammographic Texture Features","A Cohort Study on feMale Patients' mammogRaphic texturE featureS: the COMPRESS Trial","COMPRESS","Inclusion Criteria:\n\n* Candidate is a biological female aged 18 years or above;\n* Candidate is willing and able to give informed consent and gives their written consent for the participation in the study;\n* There is a clinical indication for a uni- or bilateral mastectomy\n\nExclusion Criteria:\n\n* Candidate lacks the capacity to provide informed consent;\n* Candidate has breast implants","FEMALE","18 Years",{"count":52,"type":20},200,[23],"Mammography is the most common method for breast imaging, and it provides information for model building and analysis. Radiomics applied to mammography has the potential to revolutionize clinical decision-making by providing valuable insights into risk assessment and disease detection. Despite this, the influence of imaging parameters and clinical and biological factors on radiological texture features remains poorly understood. There is a pressing need to overcome the obstacle of system-inherent effects on mammographic images to facilitate the translation of radiological texture features into routine clinical practice by enabling reliable and robust AI-based or AI-aided decision-making. Furthermore, understanding the relationship between imaging parameters, textural features, and clinical and biological information supports the clinical use of AI. The objective of this study is to evaluate AI methods for clinical practice and to study how it relates to clinical factors and biological features.",[56,57,58],"Breast Cancer","Artificial Intelligence","Mammography","2026-08-04",{"date":61,"type":32},"2026-08-05",{"date":63,"type":32},"2024-06-17",{"date":65,"type":20},"2038-12-15",{"name":38,"class":39},{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":12,"sex":74,"minAge":4,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":40},"100649819","a-cohort-study-on-factors-leading-to-vulnerability-in-adult-patients-with-serious-medical-conditions-the-cosmos-i-trial-100649819","NCT07740239","A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial","COSMOS-I","Inclusion Criteria:\n\n* Suspected or diagnosed disease\n* ≥60 years old patients, except for patients receiving high-dose chemotherapy and stem cell transplantion who need to be ≥18 years old\n* Cross-sectional imaging maximum 45 days prior to consenting or before the next treatment line\n* Patients with cancer (other than patients with prostate cancer treated with hormonal treatment before radiation treatment): study procedures (excluding image analyses) must have been carried out maximum 1 month prior to the start of a new treatment line\n* Patients with prostate cancers receiving hormonal treatment before radiation treatment): study procedures (excluding image analyses) must be carried out maximum 3 months after the start of hormonal treatment\n* Patients with other conditions: study procedures (excluding image analyses) must have been carried out maximum 4 days after the start of the hospitalization\n\nExclusion Criteria:\n\n* Not willing or unable to give written consent\n* Patient not deemed suitable for the study by the researcher approaching the patient","MALE",{"count":76,"type":20},2050,"OBSERVATIONAL","The objective of this prospective multicentre study that recruits altogether 1500 older patients from the university hospitals of Tampere, Kuopio, and Oulu is to explore the clinical significance and detection of causes of generalized vulnerability. The objectives are:\n\nO1 - Establish the prevalence of causes of generalized vulnerability among patients diagnosed with severe yet non-malignant diseases and local\u002Flocally advanced and advanced cancers, O2 - Study how causes of generalized vulnerability affect the time between the diagnosis and the adoption of a fully palliative treatment line, overall survival, and patient-reported quality of life in older adults severe diseases, and O3 - Evaluate how screening tools commonly used in patients without cancer perform in screening for causes of vulnerability in older adults with cancer",[80,81,82,83,84],"Pelvic Fracture","Prostate Cancer","Lung Cancer","Brain Metastasis","Chronic Subdural Hematoma","2026-07-28",{"date":87,"type":32},"2026-07-31",{"date":89,"type":32},"2024-11-13",{"date":91,"type":20},"2030-12-30",{"name":38,"class":39},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":12,"sex":17,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":40},"100649671","obe2026---effect-of-one-year-intensive-lifestyle-treatment-in-children-with-iso-bmi-over-30kgm-and-their-families-100649671","NCT07738029","OBE2026 - Effect of One Year Intensive Lifestyle Treatment in Children With ISO-BMI Over 30kg\u002Fm² and Their Families.","Inclusion Criteria:\n\n* Informed consent of parent(s) or legally acceptable representative of subject and child assent, as age-appropriate, obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial\n* Male or female, aged 10 to 16 years\n* Tanner stage 1-5 pubertal development at the time of signing informed consent\n* ISO-BMI ≥30kg\u002Fm2\n* History of failing to lose sufficient weight with lifestyle modification as judged by the\n\nExclusion Criteria:\n\n* Treatment with any medication for the indication of obesity within the past 90 days before screening\n* Type 1 diabetes\n* Type 2 diabetes\n* Subjects with secondary causes of obesity (for example hypothalamic, monogenic or endocrine causes)\n* Uncontrolled thyroid disease at screening, in the opinion of the investigator\n* Subjects with secondary causes of obesity (for example hypothalamic, monogenic or endocrine causes)\n* History of major depressive disorder within 2 years before screening\n* Diagnosis of other severe psychiatric disorders (e.g., schizophrenia, bipolar disorder)\n* A lifetime history of suicidal attempt\n* Subjects with confirmed diagnosis of bulimia nervosa disorder\n* History or presence of pancreatitis (acute or chronic)\n* Impaired renal function defined as serum-creatinine \\>UNR for age in children unless renal function is proven normal by further assessments at the discretion of the investigator\n* History of malignant neoplasms within the past 5 years prior to the day of screening\n* Any medical condition or laboratory abnormality, including any clinically significant out-of-range vital signs, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate för the study\n* Surgery scheduled for the duration of the trial, except for minor surgical procedures, in the opinion of the investigator\n* Known or suspected abuse of alcohol or recreational drugs\n* Previous participation in this trial. Participation is defined as signed informed consent\n* Participation in any clinical trial of an approved or non-approved investigational medicinal product within 90 days before screening\n* Female who is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measure as required by local regulation or practice)\n* Treatment with glucose-lowering agent(s) within 90 days before screening (except for metformin)\n* Treatment with a GLP-1 receptor agonist within 180 days before screening\n* Known history of, or documented positive hepatitis B or C or HIV infection\n* Aspartate transaminase (AST) or alanine transaminase (ALT) ≥ 3 x upper-limit of normal\n* Creatinine clearance (CrCl) \\\u003C 60 ml\u002Fmin measured by 24-hour urine collection or estimated from the Cockcroft and Gault formula\n* Clinically significant ECG findings as judged by the investigator ((including history of clinically significant arrhythmias or conduction delays on electrocardiogram \\[ECG\\]) within 180 days before screening, new clinically significant arrhythmias, or conduction delays on ECG identified at screening)\n* Known history of other heart diseases\n* History of major depressive disorder within 2 years before screening\n* Diagnosis of other severe psychiatric disorders (e.g., schizophrenia, bipolar disorder)\n* A lifetime history of suicidal attempt\n* Suicidal behavior within 30 days before screening\n* Suicidal ideation corresponding to type 4 or 5 based on the Columbia-Suicide Severity Rating Scale (C-SSRS) within the past 30 days before screening\n* Participants with confirmed diagnosis of bulimia nervosa disorder","10 Years","16 Years",{"count":102,"type":20},20,[23],"Obesity has increased significantly in recent decades and is starting earlier than before, even before school age. In 2023, 8% of Finnish boys aged 7-12 and 4% of girls were obese, while the corresponding figures for boys aged 13-16 were 9% and 4%, respectively. Overweight and obesity are classified using age- and gender-specific BMI percentile limits, which are derived from adult (18-year-old) BMI cutoffs for overweight (BMI 25-30 kg\u002Fm²) and obesity (BMI \\> 30 kg\u002Fm²).\n\nChildhood obesity has a significant tendency to persist into adulthood. Obesity treatment and long-term weight management require an effective intervention that combines both permanent dietary modification and increased physical activity. Obesity has significant physical, psychological, social and economic impacts on both individuals and society. Obesity drug trials have always included lifestyle interventions, but their intensity and long-term follow-up data vary. In addition, for children and young people, intervention should be targeted at the entire family, if possible, because a child alone is not able to modify everyday activities. Stress, depression and other psychologically stressful factors experienced in the family increase the risk of eating habits that predispose to obesity and weight gain.\n\nThe role of the family in the development of obesity in children and adolescents is central. Parental obesity is a significant risk factor for childhood obesity. Parents' lifestyles, family eating patterns, and eating habits are linked to childhood obesity. A healthy diet, regular meal times, and appropriate portion sizes are key factors in weight management. In addition, low physical activity is associated with overweight and obesity. Excessive sitting and other sedentary activities during waking hours may contribute to the development of obesity. Computer games are a challenge in the treatment of childhood obesity, both in terms of their inactivity and addictiveness. Physical activity promotes weight management, but without permanent changes in diet, it alone is not a sufficient means of losing weight.\n\nThe most common comorbidities are hypertension, type 2 diabetes, metabolic syndrome, dyslipidemias, and fatty liver disease. Metabolic fatty liver disease (MASLD) is currently the most common chronic liver disease in children and adolescents and is mainly caused by obesity. Obesity in adolescence and high triglyceride, insulin, and sensitive CRP levels increase the risk of metabolic syndrome in adulthood. Type 2 diabetes diagnosed in adolescence is a more serious disease than type 1 diabetes, as it is part of the metabolic syndrome, is associated with obesity and several metabolic disorders, and has a shortening effect on the patient's lifespan.",[106],"Obesity & Overweight",[108,109,110,111],"Obesity","Children","Adolescent","Lifestyle","2026-07-27",{"date":114,"type":32},"2026-07-30",{"date":116,"type":32},"2026-06-17",{"date":118,"type":20},"2029-12-31",{"name":38,"class":39},{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":140,"locationsCount":141},"100635457","management-of-dyspnea-with-high--flow-nasal-therapy-100635457","NCT07552935","Management of Dyspnea With High- Flow Nasal Therapy","HFNTpal","Inclusion Criteria:\n\n* The patient is in palliative care (ICD-10 diagnostic code Z51.5 palliative care)\n* Age ≥ 18 years\n* Ability to understand the study and provide informed consent to participate\n* Significant breathlessness (NRS = Numeric Rating Scale ≥ 4).\n* The treating physician has assessed that the patient would not benefit from treatment in intensive care unit or monitor unit.\n* The treating physician has assessed that the patient would not benefit from invasive mechanical ventilation (intubation) or cardiopulmonary resuscitation.\n\nExclusion Criteria:\n\n* Decreased level of consciousness, delirium, or other lack of cooperation that prevents participation.\n* Respiratory support other than HFNT is required.\n* The patient has received HFNT during the same admission to palliative care ward or hospice.\n* The cause of dyspnea can be treated immediately.\n* Inability to provide informed consent to participate.",{"count":128,"type":20},40,[23],"Dyspnea in patients with incurable illness is a difficult symptom. Therefore, there is a need to identify new effective treatment modalities. Previous studies suggest that high-flow nasal therapy delivered via a nasal cannula (HFNT = High-Flow Nasal Therapy) may alleviate dyspnea, and similarly that directing airflow toward the face can provide relief. HFNT has been studied very little in hospice settings and on palliative care wards. The aim of this study is to determine whether HFNT is a feasible and effective treatment for relieving dyspnea in patients receiving palliative care.\n\nPatients will be recruited from the Hatanpää Palliative Care Ward and the Pirkanmaa Hospice, Tampere, Finland. The target is to recruit approximately 30-40 patients. The inclusion criteria are: age ≥18 years, ability to understand the study and provide informed consent to participate, a palliative treatment approach, and significant dyspnea.\n\nEach patient receives HFNT and fan therapy in which airflow will be directed toward the patient's face. Both treatments will last 30 minutes. Patient symptoms will be asked after the treatments. In addition, patients will be asked to rate the overall benefit they experienced from the intervention and any side effects. The primary endpoint is the relief of dyspnea with HFNT compared with fan therapy.\n\nThe study will be conducted in accordance with laws, regulations, and guidelines governing medical research, as well as good scientific practice and research ethics. The study does not involve significant risks or measurements or sampling procedures that would cause additional discomfort. All other care for the patient will be provided according to the standard practices of the treating unit, and participation in the study will not limit any necessary treatments. Identifiable information will not be disclosed for use outside the research group. Results will be reported in a manner that does not allow patients to be identified. The Ethics Committee of the Wellbeing Services County of Pirkanmaa has approved the study.\n\nIf successful, the study will significantly improve the care of the patients in palliative care.",[132,133],"Palliative Care","Breathlessness","2026-06-25",{"date":136,"type":32},"2026-06-30",{"date":138,"type":32},"2026-06-01",{"date":118,"type":20},{"name":38,"class":39},2,{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":21,"phases":150,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":40},"100642729","bergen-four-day-treatment-b4dt-for-obsessive-compulsive-disorder-100642729","NCT07644130","Bergen Four-Day Treatment (B4DT) for Obsessive-Compulsive Disorder","Inclusion Criteria:\n\n* diagnosed with obsessive-compulsive disorder\n* willingness to participate in exposure-based treatment\n\nExclusion Criteria:\n\n* intellectual disability\n* autism spectrum disorder that precludes engagement in psychotherapeutic work\n* a psychotic disorder with current psychotic symptoms\n* underweight or very rapid weight loss affecting cognition\n* severe suicidality\n* substance dependence\n* benzodiazepine medication (use of Z-drugs as sleep medication is permitted)\n* In addition, ongoing psychotherapy may prevent participating in the B4DT.",{"count":149,"type":20},65,[23],"The aim of this study is to expand access to Bergen Four-Day Treatment (B4DT) in Finland and to integrate it into psychiatric care pathways at Tampere University Hospital (TAYS). A Bergen team has been established within TAYS Psychiatry and has been trained in collaboration with the B4DT team from HUS and the Norwegian developers. The objective of this study is to enhance understanding of the model's adaptability to the Finnish healthcare system, evaluate healthcare professionals' attitudes toward the intervention, and assess treatment outcomes.\n\nThe aim is to recruit approximately 35 patients for the study. Patients will be recruited from a minimum of three groups (15 patients) and up to a maximum of six groups (35 patients). The criteria for admission to B4DT and for participation in the study are identical. The treatment and the study may include patients receiving specialized psychiatric care at Tampere University Hospital who have been diagnosed with obsessive-compulsive disorder and who experience significant impairment due to their symptoms. In addition, personnel from TAYS Psychiatry who recommend and refer patients for B4DT will be recruited for the study. The estimated number of participating staff members is approximately 30.",[153],"Obsessive Compulsive Disorder (OCD)",[155,156,157,158],"Bergen","B4DT","intensive treatment","OCD","NOT_YET_RECRUITING","2026-06-11",{"date":162,"type":32},"2026-06-12",{"date":164,"type":20},"2026-06",{"date":166,"type":20},"2027-12",{"name":38,"class":39},{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":17,"minAge":176,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":21,"phases":180,"briefSummary":182,"conditions":183,"keywords":187,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":40},"100642387","phase-2-vancomycin-efficacy-in-response-to-dysbiosis-in-atypical-colitis-100642387","NCT07646223","Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis","The Efficacy of Oral Vancomycin Therapy in Managing Different Phenotypes of Paediatric Inflammatory Bowel Diseases by Correlating Treatment Response to Commensal Microbiota Composition and Function","VERDA","Inclusion criteria.\n\n* children aged 6-15 years\n* able to swallow capsules\n* are scheduled for diagnostic endoscopy at Tampere University\n* has not received oral vancomycin before\n* do not have active infection (such as clostridium or other bacteria)\n* has not received new interventions (medications or new conventional therapies) for treating IBD was given within the past 4 weeks before starting OVT.\n\nExclusion Criteria:\n\n* The presence of PSC without UC, Crohn's disease type of inflammatory bowel diseases.\n* Under the age of 6 years old.\n* Is unable to swallow capsules.\n* Had a previous allergic reaction to vancomycin (such as vancomycin allergy) and\u002For other related antibiotics similar to vancomycin.\n* Presence of malignant disease or potential need for liver transplantation within the following 12 months.\n* Pregnancy\n* Known renal insufficiency or chronic renal disease","6 Years","15 Years",{"count":179,"type":20},140,[181],"PHASE2","The goal of this clinical trial is to learn how oral vancomycin therapy may contribute in treating paediatric inflammatory bowel disease, particularly atypical ulcerative colitis and PSC-associated colitis. It will also give more information on how this treatment affects gut microbiota and metabolism.\n\nThe main questions it aims to answer are:\n\n1. Does oral vancomycin improve disease activity and lead to remission (based on symptoms, biomarkers, and endoscopy findings)?\n2. How does oral vancomycin change gut metabolism?\n3. Does different types of colitis respond differently to oral vancomycin?\n\nResearchers will compare children receiving oral vancomycin plus standard therapy to those receiving standard therapy alone. The gut metabolisim before and after oral vancmycin will also be compared, as well as to healthy controls and children with typical ulcerative colitis.\n\nParticipants will:\n\n1. Take oral vancomycin (if assigned) together with conventional treatment for at least 3 months and up to 12 months depending on response\n2. Visit the clinic approximately every 3 months for checkups, tests, and monitoring\n3. Provide blood, stool, and saliva samples to study disease activity and microbiota activity\n4. Undergo clinical assessments such as symptom scoring, imaging, and possibly endoscopy\n5. Complete questionnaires about quality of life\n6. Be monitored for side effects and treatment response throughout the study period",[184,185,186],"Ulcerative Colitis (UC)","Primary Sclerosing Cholangitis (PSC)","Pediatric Inflammatory Bowel Diseases",[188,189,190,191,192],"PSC-UC","atypical UC","oral vancomycin","colitis","PIBD","2026-06-09",{"date":162,"type":32},{"date":196,"type":20},"2026-08-01",{"date":198,"type":20},"2035-12-31",{"name":38,"class":39},{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":21,"phases":211,"briefSummary":212,"conditions":213,"keywords":217,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":231},"100636535","the-finnish-uterine-prolapse-surgery-trial-the-fin-up-trial-100636535","NCT07566949","The Finnish Uterine Prolapse Surgery Trial (The Fin-UP Trial)","Manchester Procedure Versus Vaginal Hysterectomy for Women With Uterine Prolapse: A Multi-Center Randomized Controlled Study (The Fin-UP Trial)","Fin-UP","Inclusion Criteria:\n\n* Fit for elective vaginal surgery according to standard preoperative assessment\n* Women aged over 18 years\n* No previous POP surgery\n* Symptomatic POP stage 2 or higher, with uterine descent of at least stage 2 (POP-Q point C ≥ minus 1) and with POP-Q point D ≤ minus 1. Patients with concurrent anterior or posterior compartment defects will be included.\n\nExclusion Criteria:\n\n* Pregnancy or future plans of pregnancy\n* Active malignancy of any kind\n* Contraindications for uterine preservation, i.e. suspected cervical or uterine malignancy, abnormal cervical cytology, abnormal uterine bleeding, a history of endometrial hyperplasia with atypia, or a known hereditary cancer syndrome involving the uterus (e.g., Lynch syndrome). All patients will undergo a clinical examination and ultrasound assessment prior to recruitment. If clinically indicated, a Pap-smear and\u002For endometrial biopsy will be performed prior to inclusion.\n* Contraindication to vaginal hysterectomy (e.g. extensive intra-abdominal adhesions)\n* Patient's preference for uterine removal or preservation\n* Planned concomitant incontinence procedure\n* Inability to speak Finnish or Swedish, understand the purpose of the study, or commit to follow-up","100 Years",{"count":210,"type":20},426,[23],"The goal of this clinical trial is to compare the Manchester procedure and vaginal hysterectomy in treating patients with symptomatic uterine prolapse.\n\nThe main question it aims to answer is:\n\n• What is the difference in the success rates at the the two year follow-up\n\nParticipants will:\n\n* be randomized in either the Manchester procedure or vaginal hysterectomy group and operated as such\n* visit the clinic at 2 and 5 years after the operation\n* fill in questionnaires at 1, 2, 5 and 10 years after the operation",[214,215,216],"Uterine Prolapse","Pelvic Organ Prolapse Vaginal Surgery","Pelvic Organ Prolapse (POP)",[218,219,220,221,222],"Uterine prolapse","Pelvic organ prolapse","Manchester procedure","Vaginal hysterectomy","Vaginal surgery","2026-05-06",{"date":225,"type":32},"2026-05-11",{"date":227,"type":20},"2026-05",{"date":229,"type":20},"2041-12",{"name":38,"class":39},6,{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":17,"minAge":240,"maxAge":176,"enrollmentInfo":241,"targetDuration":4,"studyType":21,"phases":243,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":261,"locationsCount":40},"100639046","phase-3-finnish-childrens-protracted-cough-100639046","NCT07582549","Finnish Children´s Protracted Cough","A Randomized, Double-blinded Clinical Trial Comparing the Efficacy of Antibiotic or Inhaled Corticosteroid to Placebo in Children´s Protracted Cough","FINNCHICO","Inclusion Criteria:\n\n* Prolonged cough lasting continuously for more than 4 weeks\n* No chronic disease requiring continuous medication (i.e. a generally healthy child)\n* No previous physician-diagnosed condition associated with prolonged cough episodes\n* No physician-identified symptoms or findings suggestive of an underlying disease\n* No prior physician-diagnosed allergic reaction or other severe or life-threatening adverse reaction to the investigational medicinal products (fluticasone or amoxicillin-clavulanic acid)\n* No simultaneous participation in another clinical drug trial\n* Parents\u002Fguardians have sufficient spoken and written Finnish language proficiency\n* Written, voluntary informed consent provided by a parent or legal guardian\n\nExclusion Criteria:\n\nChildren with symptoms or findings suggestive of an underlying cause of cough, including:\n\n* A previously physician-diagnosed disease associated with prolonged cough\n* Clinical examination or history at the study visit raising suspicion of a disease associated with prolonged cough (positive \"cough pointers\")\n* Abnormal lung function test\n* Abnormal chest X-ray (peribronchial markings are permitted)\n\nAdditional exclusion criteria:\n\n* Prior physician-diagnosed allergic reaction or other severe or life-threatening adverse reaction to the investigational medicinal products\n* Simultaneous participation in another clinical drug trial\n* Prolonged cough that has resolved spontaneously prior to the study visit","1 Year",{"count":242,"type":20},100,[244],"PHASE3","Prolonged cough lasting more than four weeks is common in children, but the best treatment is often unclear when no underlying disease can be found. This study aims to find out whether commonly used treatments help children with prolonged cough more effectively than placebo.\n\nChildren who take part will first undergo standard medical examinations, including lung function tests and a chest X-ray, to look for the cause of the cough. If no specific cause is found, the child may enter the study.\n\nChildren with a dry cough will be randomly assigned to receive either an inhaled corticosteroid (fluticasone) or a placebo inhaler for two months. Children with a wet or productive cough will be randomly assigned to receive either an oral antibiotic (amoxicillin-clavulanic acid) or a placebo medicine for 14 days. Neither the families nor the researchers will know which treatment the child receives during the study.\n\nThe main goal is to determine whether these treatments significantly reduce or stop the cough compared with placebo. The results will help improve treatment recommendations for children with prolonged cough and avoid unnecessary medication use.\n\nParticipation is voluntary, and parents provide written informed consent for their child.",[247],"Chronic Cough",[247,249,250,251,252,253,254],"Child","Fluticasone Propionate","Amoxicillin-Potassium Clavulanate Combination","Randomized Controlled Trial","Double-Blind Method","Phase III","2026-05-05",{"date":257,"type":32},"2026-05-13",{"date":259,"type":32},"2025-12-22",{"date":166,"type":20},{"name":38,"class":39},{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":100,"enrollmentInfo":268,"targetDuration":4,"studyType":21,"phases":270,"briefSummary":271,"conditions":272,"keywords":274,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":40},"100637420","phase-3-continuous-antibiotic-infusion-in-children-100637420","NCT07575009","Continuous Antibiotic Infusion In Children","Inclusion Criteria:\n\n* iv-antibiotic treatment is necessary\n* clinically stable\n* no need to stay in hospital\n* pump or cassette can be changed at the hospital or at home\n* care givers are able to contact hospital if needed\n* clinical diagnose is not uncertain\n* no allergy for the used antibiotic\n* the continuous antibiotic infusion hasn't been started yet or it has been initiated no more than 24 hours prior to study enrolment\n\nExclusion Criteria:\n\n* the pump cannot be carried with the child\n* the child must stay at the hospital for monitoring or other reason\n* unclear diagnose",{"count":269,"type":20},150,[244],"Continuous intravenous antibiotic infusion using elastomeric pumps is well established in adult care and has been shown to be effective, safe, and cost-efficient, particularly for beta-lactams and vancomycin. In pediatric outpatient parenteral antimicrobial therapy (p-OPAT), home intravenous treatment is feasible and safe, improves quality of life, and reduces hospital stays and healthcare-associated infections. Elastomeric pumps offer practical advantages, including portability, ease of use, fixed infusion rates, and reduced drug handling, although they are limited by fixed flow rates and drug stability.\n\nThis prospective study at Tampere University Hospital (Tays) will evaluate the safety and cost-effectiveness of 24-hour continuous antibiotic infusions in children between January 2026 and January 2029. Eligible pediatric patients requiring intravenous antimicrobial treatment and suitable for home care will be included. Indications include serious bacterial infections such as bacteremia, osteomyelitis, septic arthritis, neutropenic fever, cystic fibrosis-related infections, and foreign body infections. The study antibiotics are benzylpenicillin, cloxacillin, piperacillin\u002Ftazobactam, and vancomycin, administered via CE-approved infusion devices for home use.\n\nChildren will receive continuous infusion either initially in hospital or directly from the emergency department if appropriate, with treatment duration and dosing comparable to standard intermittent regimens. Outcomes include safety, feasibility, cost-effectiveness, and patient-reported quality of life measured using PedsQL™. The study aims to determine whether continuous infusion can optimize pediatric antimicrobial care and healthcare resource utilization. Results will be published in peer-reviewed international journals.",[273],"Infection",[275,109,276,277,278],"Continuous antibiotic infusion","sepsis","osteomyelitis","Elastomeric pump","2026-05-04",{"date":281,"type":32},"2026-05-08",{"date":283,"type":32},"2026-04-21",{"date":285,"type":20},"2031-12-31",{"name":38,"class":39},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":295,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":296,"targetDuration":298,"studyType":77,"phases":4,"briefSummary":299,"conditions":300,"keywords":304,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":323,"locationsCount":324},"100635718","histomolecular-profiling-in-small-bowel-diseases-100635718","NCT07556328","Histomolecular Profiling in Small-Bowel Diseases","Histological and Molecular Profiling in the Diagnostics and Treatment of Small-Bowel Diseases - A Prospective Cohort Study (The DeepBowel Study)","Deep Bowel","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Clinically indicated upper gastrointestinal endoscopy (gastroscopy)\n* Written informed consent obtained prior to procedure\n* For Group 1 (Healthy Controls): Negative celiac disease antibodies (anti-transglutaminase and\u002For anti-endomysium); no suspected celiac\n* For Group 2 (Celiac Diagnostics): Referred for primary celiac disease diagnostics requiring duodenal biopsy\n* For Group 3 (Refractory Injury): Confirmed small-bowel mucosal injury not responsive to a gluten-free diet\n\nExclusion Criteria:\n\n* For Group 1 (Healthy Controls): Other small-bowel diseases causing mucosal injury, including Crohn's disease and small-bowel ulcers\n* Inability to provide written informed consent\n* Refusal to participate",true,{"count":297,"type":20},300,"12 Months","This prospective cohort study aims to establish reliable histological reference values for normal small-bowel mucosa, improve histological diagnostic quality in celiac disease, and develop an advanced molecular profile for disease diagnosis and treatment response evaluation. The study will collect duodenal biopsies from three groups: healthy controls undergoing clinically indicated gastroscopy, patients referred for primary celiac disease diagnostics, and patients with small-bowel mucosal injury unresponsive to a gluten-free diet. Patients will undergo routine clinical assessment via standard pathology review of diagnostic biopsies. Biopsies will be analyzed using digital morphometry, AI-based image analysis, RNA sequencing (transcriptomics), and intestinal organoid cultures.",[301,302,303],"Celiac Disease","Small Bowel Disease","Refractory Celiac Disease",[305,306,307,308,309,310,311,312,313,314,315,316],"celiac disease","duodenal biopsy","histology","digital morphometry","artificial intelligence","RNA sequencing","transcriptomics","organoids","small bowel","villous atrophy","molecular profiling","machine learning","2026-04-24",{"date":319,"type":32},"2026-04-29",{"date":321,"type":32},"2025-11-01",{"date":198,"type":20},{"name":38,"class":39},3,{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":332,"enrollmentInfo":333,"targetDuration":4,"studyType":21,"phases":335,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":347},"100633603","health-effects-of-mindfulness-based-stress-reduction-course-in-treatment-of-back-pain-100633603","NCT07528833","Health Effects of Mindfulness Based Stress Reduction Course in Treatment of Back Pain","Health Effects of Mindfulness Based Stress Reduction Course Versus Usual Care in Treatment of Back Pain: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Working-age (18-64 years) patients\n* Back pain in thoracal or lumbar area\n* NRS at least 4\n* With or without radiculative symptoms\n* Pain duration over 12 weeks\n* Pain can be localized or widespread\n* Also patients with multiple pain are eligible\n* X-ray or MRI scan is not needed\n* Patients can be both gender\n* Finnish language skills and adequate competence are needed for filling the survey forms and participation in interventions\n\nExclusion Criteria:\n\n* Pregnancy\n* Recent delivery (\\\u003C12 months)\n* Mental health problems with psychotic symptoms\n* Acute severe psychological trauma (3 months)\n* Sings of back infection\n* Acute severe trauma in the back (fracture)\n* surgery (\\\u003C 6 months)\n* planned surgery in the future\n* tumor in the back","64 Years",{"count":334,"type":20},120,[23],"* Health effects of mindfulness based stress reduction course versus usual care in treatment of back pain: a randomized clinical trial\n* Mindfulness based stress reduction (MBSR) course intervention for half of the research patients\n* MBSR course lasts for 8 weeks.\n* follow-up time 2 years.\n* research data is collected by Recdap\n* Working-age (18-64 years) patients with back pain in thoracal or lumbar area (NRS at least 4) with or without radiculation over 12 weeks will be recruited.\n* The primary outcome measure is Numeric pain rating scale (NRS, 0-10).",[338],"Back Pain","2026-04-07",{"date":341,"type":32},"2026-04-14",{"date":343,"type":32},"2025-01-01",{"date":345,"type":20},"2030-01-01",{"name":38,"class":39},4,{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":21,"phases":358,"briefSummary":359,"conditions":360,"keywords":364,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":141},"100630163","efficacy-of-proximal-median-nerve-release-100630163","NCT07484100","Efficacy of Proximal Median Nerve Release","Efficacy of Operative Versus Conservative Treatment in Proximal Median Nerve Compression","PROMER","Inclusion Criteria:\n\n1. Clinically diagnosed PMNC\n2. If the patient has clinically and electrodiagnostically confirmed carpal tunnel syndrome, at least 6 months must have passed since surgical treatment\n3. Age 18 or over\n4. Ability to understand Finnish\n5. Ability to complete electronic questionnaires independently\n6. Willingness to participate in research and follow research instructions\n7. Provision of informed consent from the participant\n\nExclusion Criteria:\n\n1. Nerve root disorder findings in ENMG\n2. Thoracic outlet syndrome, TOS\n3. Other neurological condition that causes upper limb symptoms such as MS, previous nerve injury\n4. Active rheumatoid arthritis or any other active inflammatory joint disease that affects hand function\n5. Significant compression symptoms of another peripheral nerve in association with PMNC\n6. Other upper extremity operation performed less than 6 months ago\n7. Another disease or condition that accounts for most of the patient's symptoms\n8. Other known reasons that may prevent participation or implementation of treatment during the study",{"count":357,"type":20},160,[23],"A multi-center randomized controlled clinical trial which determines the efficacy of proximal median nerve release in patients with persistent proximal median nerve compression. The primary outcome is patient reported improvement of symptoms on a 7-point Likert scale at 6 months after the randomization to treatment group.",[361,362,363],"Carpal Tunnel Surgery","Median Nerve Compression","Median Nerve Entrapment",[365,366,367,368],"proximal median nerve entrapment","proximal median nerve compression","proximal median nerve release","randomized controlled trial","2026-03-17",{"date":371,"type":32},"2026-03-19",{"date":373,"type":20},"2026-03-01",{"date":375,"type":20},"2041-07",{"name":38,"class":39},{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":21,"phases":386,"briefSummary":387,"conditions":388,"keywords":390,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":40},"100625536","pro-rstap-effect-of-tap-and-rs-blocks-on-recovery-after-inguinal-hernia-surgery-pro-rstap-100625536","NCT07423910","PRO-RSTAP: Effect of TAP and RS Blocks on Recovery After Inguinal Hernia Surgery (PRO-RSTAP)","Effect of Medial Transversus Abdominis Plane (TAP) Block and Rectus Sheath (RS) Block on Inguinal Hernia Surgery Recovery, a Prospective Randomized Double-blind Study (PRO-RSTAP)","PRO-RSTAP","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Elective unilateral open inguinal hernia repair\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Emergency surgery\n* Bilateral or recurrent inguinal hernia\n* Contraindication to regional anesthesia or study interventions\n* Known allergy to local anesthetics\n* Inability to comply with study procedures",{"count":52,"type":20},[23],"Inguinal hernia repair is a common surgical procedure, often performed as day-case surgery. Despite standardized surgical techniques, postoperative pain may delay recovery and occasionally lead to unplanned hospital admission.\n\nThe PRO-RSTAP study is a prospective, randomized, double-blind clinical trial evaluating whether ultrasound-guided transversus abdominis plane (TAP) block, rectus sheath (RS) block, or their combination improves postoperative recovery after open inguinal hernia surgery. Adult patients undergoing unilateral open inguinal hernia repair are randomized into four groups receiving either combined TAP and RS blocks, TAP block only, RS block only, or placebo blocks , in addition to standard perioperative care.\n\nThe primary outcome is total perioperative opioid consumption measured as intravenous morphine equivalents. Secondary outcomes include postoperative pain scores, need for rescue analgesia, postoperative nausea and vomiting, time to discharge, unplanned hospital admission, and chronic postoperative pain during long-term follow-up.\n\nThe aim of this study is to determine the individual and combined effects of TAP and RS blocks on postoperative analgesia and recovery in patients undergoing open inguinal hernia repair.",[389],"Inguinal Hernia",[391,392,393,394,395],"Open inguinal hernia repair","Regional anesthesia","Transversus abdominis plane block","Rectus sheath block","Postoperative analgesia","2026-02-13",{"date":398,"type":32},"2026-02-20",{"date":400,"type":32},"2025-07-01",{"date":402,"type":20},"2038-01",{"name":38,"class":39},{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":413,"conditions":414,"keywords":419,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":432,"leadSponsor":434,"locationsCount":40},"100621094","long-term-health-outcomes-of-screen-detected-and-potential-celiac-disease-patients-100621094","NCT07366151","Long-term Health Outcomes of Screen Detected and Potential Celiac Disease Patients","The Impact of Active Screening on the Long-term Health of Celiac Disease Patients and the Natural Course of Potential Untreated or Treated Celiac Disease","Inclusion Criteria:\n\n* Finnish citizenship and current residence in Finland\n\nExclusion Criteria:\n\n* Age \\\u003C18 years",{"count":412,"type":20},250,"The primary aim of this project is to investigate how active screening and the timing of diagnosis affect the long-term health outcomes of patients with celiac disease. Additionally, the study seeks to clarify the natural course of so-called potential celiac disease. A key focus is also placed on assessing adherence to a gluten-free diet among screen-detected and, if initiated, potential celiac disease patients, their satisfaction with the diagnosis, and the diet's impact on general health and quality of life.",[415,416,417,418,301],"Malabsorption Syndromes","Intestinal Diseases","Gastrointestinal Disease","Digestive System Diseases",[420,421,422,423,424,425,426,427],"Celiac disease","Potential celiac disease","Gluten-free diet","Screen detected","Long-term health","Quality of life","Symptoms","Asymptomatic","2026-01-23",{"date":430,"type":32},"2026-01-26",{"date":373,"type":20},{"date":433,"type":20},"2034-12",{"name":38,"class":39},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":21,"phases":445,"briefSummary":446,"conditions":447,"keywords":453,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":347},"100605430","ganglion-resection-effectiveness-trial-100605430","NCT07162415","Ganglion Resection Effectiveness Trial","GangLion Resection Effectiveness Trial (GangLion): a Multicentre, Randomized, Superiority Trial","GangLion","Inclusion Criteria:\n\n* wrist pain located in the ganglion area\n* diagnosis of ganglion of the wrist, based on clinical examination or imaging findings\n* age over 18 years\n* ability to fill out the Finnish or English version of the questionnaires\n\nExclusion Criteria:\n\n* pregnant or breast feeding\n* other known wrist pathology that likely explains the pain\n* previous surgical treatments of the wrist\n* wrist ganglion presumed to be related to a work injury",{"count":444,"type":20},220,[23],"The goal of this clinical trial is to learn if surgery helps with wrist ganglions in adults. The main question it aims to answer is:\n\n* Does surgery result in better patient-reported outcomes and satisfaction over a 6-months follow-up period?\n\nResearchers will compare surgery to conservative treatment (self-administered exercises and use of the hand as tolerated) to see if surgery provides superior outcomes.\n\nParticipants will:\n\n* Be randomly assigned to receive either surgery or conservative treatment\n* Complete questionnaires about wrist pain, function, quality of life, satisfaction, and recovery at 3, 6, and 12 months",[448,449,450,451,452],"Wrist Ganglion","Ganglion","Ganglion Cyst","Connective Tissue Disease","Mucinoses",[454,455],"ganglion","wrist","2026-01-19",{"date":458,"type":32},"2026-01-21",{"date":460,"type":32},"2026-01-13",{"date":462,"type":20},"2035-12",{"name":38,"class":39},{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":17,"minAge":472,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":21,"phases":475,"briefSummary":476,"conditions":477,"keywords":481,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":487,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":493},"100596183","no-reduction-compared-to-closed-reduction-for-distal-radius-fractures-in-patients-over-65-or-older-100596183","NCT07042139","No Reduction Compared to Closed Reduction for Distal Radius Fractures in Patients Over 65 or Older","A Randomized Controlled Trial Comparing No Reduction to Closed Reduction for Distal Radius Fractures in Patients 65 Years and Older (DISCLOSE Trial): A Study Protocol","DISCLOSE","Inclusion Criteria:\n\n* Age 65 years or older\n* Independent living patients\n* Displaced distal radius fracture (AO\u002FOTA 23A\u002F23C) with 15-40 degree dorsal angulation, and\u002For of shortening of the radius for more than 2 mm.\n* Associated ulnar styloid fracture is permitted\n* Low energy injury, (fall from \\\u003C1 m)\n\nExclusion Criteria:\n\n* Patient unable to provide consent\n* Patients who are actively working in a paid position\n* Volar angulation, partial articular fractures (AO\u002FOTA 23B)\n* Concomitant fracture of the ulna proximal to the base of the styloid process\n* Associated fracture or dislocation in any other body part that would affect the use of the injured distal radius\n* Distal radius fractures in both arms\n* Open injury, Gustilo 2 or higher\n* No bony contact between the main fragments\n* High energy injuries","65 Years",{"count":474,"type":20},532,[23],"DISCLOSE trial is a randomized controlled trial including 532 participants with low-energy distal radius fractures. The primary objective is to evaluate whether casting without prior closed reduction is equivalent to casting following closed reduction with respect to wrist-related pain and disability, as measured by the Patient-Rated Wrist Evaluation (PRWE) score at 12 months, in patients aged 65 years or older with a displaced distal radius fracture.\n\n* Primary endpoint will be PRWE at 12 months\n* Follow-up visits are scheduled at 3 and 12 months. 5-year follow-up will be considered as an exploratory endpoint",[478,479,480],"Distal Radius Fracture","Casting","Closed Reduction",[482,483,484,485,486],"distal radius fracture","casting","closed reduction","nonoperative treatment","DISCLOSE trial",{"date":458,"type":32},{"date":489,"type":32},"2025-08-01",{"date":491,"type":20},"2033-07-01",{"name":38,"class":39},10,{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":500,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":503,"conditions":504,"keywords":508,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":4},"100617203","couples-and-microbial-diversity-100617203","NCT07315568","Couples and Microbial Diversity","COUPLES AND MICROBIAL DIVERSITY","CLARITY","Inclusion Criteria:\n\n* Problems in conceiving the past 12 months\n* Over 18 years old\n* Fluent in Finnish\n\nExclusion Criteria:\n\n* Needs for donated gametes (except for female homosexual couples)",{"count":52,"type":20},"Couples and Microbial Diversity (CLARITY) - study is a prospective study that investigates the risks and dynamics of different microbes and transmission among couples to optimize the prevention and control strategies as well as improvement for infertility treatments.\n\nThe study will be conducted at the Infertility Clinic of Tampere University Hospital, Tampere Finland; and will recruit 200 couples undergoing infertility investigations and treatments. Oral and genital tract samples will be collected at baseline and every six months during a two-year follow-up period. Background information will be obtained through a secure online questionnaire.\n\nCouples who achieve pregnancy will be followed according to the CLARITY protocol until delivery, after which families will transition to the CLARITY-Baby extension study. Samples from both the newborn and parents will be collected at delivery and again at six months postpartum, accompanied by an online follow-up questionnaire completed by the parents.",[505,506,507],"Infertility","Transmission","Infections",[509,510,505,511],"Human Microbiome","HPV","Microbial Diversity","2025-12-18",{"date":514,"type":32},"2026-01-02",{"date":516,"type":20},"2026-01-05",{"date":518,"type":20},"2031-12-30",{"name":38,"class":39},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":21,"phases":530,"briefSummary":531,"conditions":532,"keywords":539,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":40},"100606447","operative-treatment-vs-treatment-with-semi-occlusive-dressing-for-single-finger-amputations-100606447","NCT07175675","Operative Treatment vs Treatment With Semi-occlusive Dressing for Single Finger Amputations","Operative Treatment vs Treatment With Semi-occlusive Dressing - a Randomized, Controlled Trial on Finger Amputations","FINACT","Inclusion Criteria:\n\n* age \\>18, single digit injury, Amputation at Tamai zones 1+2 in all digits or Tamai zones 3+4 in digits II-V, Able to understand Finnish and to complete self-reported questionnaires\n\nExclusion Criteria:\n\n* Previous partial or total amputation of the injured digit, Previous condition which affects significantly the function and\u002For symptoms of the affected hand, Patient is pregnant at the time of recruitment",{"count":529,"type":20},252,[23],"The goal of this interventional study is to find out whether conservative treatment with semi-occlusive film is superior to surgical treatment in single finger amputations in adult population. The main question it aims to answer is:\n\nIs PRWHE (Patient Reported Wrist and Hand Evaluation) total score measured at 12 months after injury better in conservatively or operatively treated patients?",[533,534,535,536,537,538],"Fingertips Traumatic Amputations","Finger Injuries","Finger","Finger Injury","Amputation, Traumatic","Amputation",[540,541,542],"finger amputation","single finger amputation","single digit amputation","2025-11-17",{"date":545,"type":32},"2025-11-21",{"date":547,"type":32},"2025-10-27",{"date":549,"type":20},"2032-01",{"name":38,"class":39},{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":295,"sex":17,"minAge":557,"maxAge":558,"enrollmentInfo":559,"targetDuration":4,"studyType":21,"phases":560,"briefSummary":561,"conditions":562,"keywords":565,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":141},"100532870","urothelial-cancer-screening-in-individuals-with-lynch-syndrome-using-a-urine-tumor-dna-panel-ls-uro-study-100532870","NCT06218433","Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study)","Inclusion Criteria:\n\n* Willing and able to provide informed consent\n* Diagnosis of Lynch syndrome\n* Age 50 - 75 years at study recruitment\n\nExclusion Criteria:\n\n* Concurrent urothelial carcinoma","50 Years","75 Years",{"count":52,"type":20},[23],"Lynch syndrome (LS) is an inherited cancer predisposition syndrome caused by pathogenic germline variants in DNA mismatch repair (MMR) genes. New cancer screening and diagnostic tools are urgently needed to identify LS-related cancers early enough for curative treatment. Urothelial cancers (comprising bladder and upper tract urothelial tumors) are the third most common cancer after colorectal and endometrial cancers in individuals with LS. Up to one in four LS individuals will develop urothelial cancer during their lifetime, with the risk varying based on the defective MMR gene. In this clinical trial, we will employ urine tumor DNA (utDNA) to identify asymptomatic urothelial cancers in Lynch syndrome patients, and to investigate the potential benefits of urine tumor DNA based screening in this high-risk population.",[563,564],"Urothelial Carcinoma","Lynch Syndrome",[566,567,568,569,570,571,572,573,574],"Lynch syndrome","Hereditary cancer syndrome","Screening","Urothelial neoplasms","Bladder neoplasms","Upper tract urothelial neoplasms","Urogenital diseases","Liquid biopsies","Urine tumor DNA",{"date":576,"type":32},"2025-11-18",{"date":578,"type":32},"2023-04-10",{"date":580,"type":20},"2034-12-31",{"name":38,"class":39},{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":208,"enrollmentInfo":590,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":592,"conditions":593,"keywords":594,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":601,"locationsCount":602},"100539970","prospective-validation-study-of-high-volume-urine-dna-testing-in-individuals-with-suspicion-of-urothelial-cancer-100539970","NCT06310759","Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer","Observational Prospective Multicenter Validation Study Investigating the Possibility of Replacing Cystoscopies With High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer (UROSCOUT-1)","UROSCOUT-1","Inclusion Criteria:\n\n* Willing and able to provide informed consent\n* Patient has been scheduled for cystoscopy to rule out urothelial cancer\n\nExclusion Criteria:\n\n* Prior diagnosis of urothelial cancer (i.e. bladder cancer or upper tract urothelial carcinoma)",{"count":591,"type":20},3000,"Urothelial cancers of the bladder and upper urinary tract account for over 200,000 deaths and 600,000 diagnoses annually worldwide. The most common presenting symptom is hematuria (blood in urine), triggering a cascade of tests, including an invasive examination of the bladder using a flexible scope (cystoscopy). Millions of cystoscopies are performed every year worldwide for patients presenting with hematuria, but only 10% result in a cancer diagnosis. The UROSCOUT-1 trial is a prospective multicenter observational study that explores the potential of urine tumor DNA (utDNA) testing to replace a significant portion of cystoscopies in the diagnostic setting for hematuria or other reasons to rule out urothelial cancer. The goal is to enhance patient quality of life, reduce healthcare costs, and address increased workloads in urology centers. Sample collection will be conducted by mail, and the samples will be analyzed in a blinded manner, without knowledge of which patients are diagnosed with cancer. Random subsampling will be applied to cancer-negative patients to achieve an approximate 1:1 ratio between cancer-positive and -negative patients.",[563],[569,570,571,573,574],"2025-10-08",{"date":597,"type":32},"2025-10-10",{"date":599,"type":32},"2024-01-08",{"date":118,"type":20},{"name":38,"class":39},8,{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":4,"eligibilityCriteria":609,"healthyVolunteers":295,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":610,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":612,"conditions":613,"keywords":615,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":40},"100485194","background-of-different-phenotypes-of-coeliac-disease-100485194","NCT05597904","Background of Different Phenotypes of Coeliac Disease","Genetic and Biological Background and Follow-up of Different Phenotypes of Coeliac Disease","Inclusion Criteria:\n\n* Cohorts 1 and 2: coeliac disease or dermatitis herpetiformis diagnosis\n* Cohort 3: friend or non-related family member of coeliac disease or dermatitis herpetiformis patient\n\nExclusion Criteria:\n\n* Cohorts 1-3: Age \\\u003C18 years\n* Cohorts 1 and 2: coeliac disease or dermatitis herpetiformis diagnosis not confirmed\n* Cohort 3: coeliac disease or dermatitis herpetiformis diagnosis",{"count":611,"type":20},3500,"The main purpose of this study is to investigate genetic, serological, immunological and microbiata diversities between different coeliac disease phenotypes and to discover applicable prognostic markers for specific phenotypes.",[301,614],"Dermatitis Herpetiformis",[616,617,618,619,620],"coeliac disease","dermatitis herpetiformis","gluten-free diet","transglutaminase","microbiata","2025-09-10",{"date":623,"type":32},"2025-09-17",{"date":625,"type":32},"2022-11-08",{"date":627,"type":20},"2030-12-31",{"name":38,"class":39},{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":4,"eligibilityCriteria":635,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":636,"targetDuration":637,"studyType":77,"phases":4,"briefSummary":638,"conditions":639,"keywords":643,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":652,"locationsCount":40},"100446546","the-cardiac-stress-and-electrocardiographic-changes-caused-by-lung-cancer-surgery-100446546","NCT05094843","The Cardiac Stress and Electrocardiographic Changes Caused by Lung Cancer Surgery","The Cardiac Stress and Electrocardiographic Changes Caused by Lung Cancer Surgery.","Inclusion Criteria:\n\n* Adult patients scheduled for elective lung cancer surgery\n* Willing to participate in the study\n* Curatively aimed surgery\n* Preoperative decision for mini-invasive surgery\n\nExclusion Criteria:\n\n* Participation in any other clinical trial\n* Previous chronic or paroxysmal atrial fibrillation or atrial flutter\n* Cardiac pacemaker\n* History of cardiac conduction disturbances including bundle branch blocks\n* History of cardiac ablation procedures\n* History of previous surgery in the thoracic area including open heart surgery\n* Preoperatively anticipated need for concomitant thoracic wall resection\n* Preoperatively anticipated need for open surgery",{"count":242,"type":20},"3 Weeks","Lung cancer surgery causes significant changes in the small circulation as well as changes in the intrathoracic anatomy. The effects of lung cancer surgery on electrocardiography and the cardiac stress associated with the procedures have not been previously extensively studied. The aim of the present study is to ascertain whether modern mini-invasive lung cancer surgery causes changes in the electrocardiogram, and whether these changes are transitory during short-term follow-up. Furthermore, the study aims to describe whether lung cancer surgery causes significant cardiac stress detectable by intraoperative electrocardiography.",[82,640,641,642],"Surgery","Arrhythmia","Myocardial Ischemia",[644,645,641],"Lung cancer","Electrocardiogram","2025-09-03",{"date":621,"type":32},{"date":649,"type":32},"2022-03-01",{"date":651,"type":20},"2028-12-31",{"name":38,"class":39},{"id":654,"slug":655,"hasResults":12,"nctId":656,"briefTitle":657,"officialTitle":658,"acronym":659,"eligibilityCriteria":660,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":661,"targetDuration":4,"studyType":21,"phases":662,"briefSummary":663,"conditions":664,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":667,"lastUpdatePostDateStruct":668,"startDateStruct":670,"completionDateStruct":672,"leadSponsor":674,"locationsCount":675},"100541323","nordic-organ-preservation-pilot-approach-nonrandomised-single-arm-trial-for-non-operative-management-of-rectal-cancer-100541323","NCT06328361","Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer","Nordic ORgan Preservation Pilot Approach - A Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer (NORPPA-1)","NORPPA-1","Inclusion Criteria:\n\n* Histopathological verification of primary rectal adenocarcinoma\n* Complete clinical response at response assessment after neoadjuvant therapy\n* Informed consent to organ preservation study\n\nExclusion Criteria:\n\n* Evidence of metastatic disease (fulfilling M-class criteria of TNM)\n* No neoadjuvant therapy\n* Inability to understand the information related to harms and benefits",{"count":52,"type":20},[23],"The goal of this one-arm clinical trial is to implement and study the oncological outcomes of nonoperative management of rectal cancer having complete clinical response to neoadjuvant therapy. The main questions to answer are\n\n* if the oncological results of nonoperative management after Nordic practice in chemoradiotherapy indications differ from experiences elsewhere\n* what is the organ preservation rate\n* what is the local regrowth rate",[665,666],"Rectal Cancer","Rectal Adenocarcinoma","2025-08-25",{"date":669,"type":32},"2025-09-02",{"date":671,"type":32},"2024-05-16",{"date":673,"type":20},"2032-12-31",{"name":38,"class":39},13,{"id":677,"slug":678,"hasResults":12,"nctId":679,"briefTitle":680,"officialTitle":681,"acronym":4,"eligibilityCriteria":682,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":683,"targetDuration":685,"studyType":77,"phases":4,"briefSummary":686,"conditions":687,"keywords":690,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":694,"lastUpdatePostDateStruct":695,"startDateStruct":697,"completionDateStruct":699,"leadSponsor":700,"locationsCount":4},"100602859","need-driven-treatment-of-the-patients-with-type-1-diabetes-100602859","NCT07128992","Need-driven Treatment of the Patients With Type 1 Diabetes","The Impact of Need-driven Treatment of Insulin-Deficient Diabetes on the Care Events, Glycemic Control, Risk Factors, and Complications in the Pirkanmaa Wellbeing Services County, Finland","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of type 1 diabetes\n* Treatment with multiple daily injections or insulin pump therapy\n* Duration of diabetes ≥ 1 year\n* Good glycemic control over the previous two weeks, defined as:\n* HbA1c \\\u003C 53 mmol\u002Fmol\n* Time in Range (TIR) \\> 70%\n* Time Below Range (TBR) \\\u003C 4%\n* Time Above Range (TAR) \\\u003C 25%\n* Use of a continuous glucose monitoring system connected via a smartphone application\n* Under specialist diabetes care within the Pirkanmaa Wellbeing Services County (Pirha)\n* Willing to accept remote diabetes care by granting the diabetes team at Tampere University Hospital access to glucose data\n* No need for regular specialist care due to other medical conditions\n* Provides informed consent to participate in the study\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Duration of diabetes \\\u003C 1 year\n* Pregnancy\n* Not using multiple daily injections or insulin pump therapy\n* Not using a continuous glucose monitoring system\n* Does not accept remote care\n* History of diabetic ketoacidosis or severe hypoglycemia within the past 12 months\n* Presence of retinopathy\n* No retinal imaging performed within the past 12 months\n* Urine albumin-creatinine ratio (uACR) \\> 3 mg\u002Fmmol or estimated glomerular filtration rate (eGFR) \\\u003C 60 ml\u002Fmin\u002F1.73 m² on two occasions over a period of more than 3 months\n* Undergoing dialysis or post-kidney transplantation\n* Cardiovascular disease (excluding hypertension)\n* Neuropathy, foot ulcer, or amputation (foot risk category 1-3)\n* Scheduled hospital outpatient visits for other specialties within the next 12 months\n* Not under specialist diabetes care within the Pirkanmaa Wellbeing Services County (Pirha)",{"count":684,"type":20},125,"24 Months","This prospective study evaluates the safety of extending the interval of routine calendar-based follow-up visits from every 12 months to every 24 months in patients with type 1 diabetes who are in good glycemic control and suitable for remote monitoring. The primary outcome is the proportion of patients who maintain good glycemic control during the 24-month follow-up period.\n\nParticipants will attend two in-person visits at baseline (month 0) and at the end of follow-up (month 24), which include a comprehensive clinical examination, assessment of glucose control, and laboratory testing. One remote contact will occur at month 12 for prescription renewal and review of glucose data. Patients may contact their care unit as needed throughout the study. At the baseline and final visits, participants will complete a questionnaire assessing their perceived ability to manage self-care, the safety of the care plan, and their ability to contact their care provider when necessary.",[688,689],"Type 1 Diabetes (T1D)","Glucose Control",[691,692,693],"type 1 diabetes","complication","glycemic control","2025-08-18",{"date":696,"type":32},"2025-08-19",{"date":698,"type":20},"2025-10-06",{"date":651,"type":20},{"name":38,"class":39},""]